MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The MoonLake class action lawsuit alleges that the company and its executives made false statements regarding the efficacy of its drug candidate, sonelokimab, leading to significant financial losses for investors [1][3][5]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's sole drug candidate, sonelokimab (SLK), is primarily aimed at treating hidradenitis suppurativa (HS) [3]. Allegations of the Lawsuit - The lawsuit claims that MoonLake and its executives failed to disclose critical information about SLK, including its molecular targets and clinical efficacy compared to Union Chimique Belge's BIMZELX [4]. - It is alleged that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide a superior clinical benefit [4]. - The lawsuit highlights that SLK's supposed increased tissue penetration did not translate to improved clinical efficacy [4]. Impact of the Allegations - Following the announcement of disappointing Phase 3 trial results on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who purchased MoonLake common stock during the class period can seek to become lead plaintiffs in the lawsuit, which allows them to represent the interests of all affected investors [6]. - The deadline for filing lead plaintiff motions is December 15, 2025 [2]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases [7].